A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Clinical trial NCT00267007 · TERMINATED

Trial details

NCT number: NCT00267007
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Peripheral Neuropathy, Chemotherapy-induced

Start date: 2006-06-01
Primary completion: 2008-08-01
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.